Features of the management of reproductive aged women with adenomyosis in the post-COVID period

In: REPRODUCTIVE ENDOCRINOLOGY · 2023 · pp. 68–73 · doi:10.18370/2309-4117.2023.67.68-73 · W4382602774
article OA: diamond CC0
AI-generated summary by claude@2026-06, 2026-06-09

This study developed and validated a personalized management algorithm for reproductive-aged women with adenomyosis post-COVID-19, showing significant improvements in symptoms and biomarkers compared to standard therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-17 · read from full text

This paper studied 120 reproductive-aged women with adenomyosis after COVID-19, stratified by severity (degrees I–II vs III–IV) and treated either with a proposed personalized diagnostic–therapeutic–preventive algorithm or with standard therapy, with evaluations before treatment and at 3, 6, and 12 months. Across groups, the proposed algorithm was reported to significantly reduce complaint frequency and exacerbations of extragenital and gynecologic pathology, stabilize blood and liver function parameters and lipid/cholesterol metabolism, lower hypercoagulation and inflammatory marker activity, increase vitamin D and magnesium, improve vaginal biocenosis, reduce detection of herpes simplex virus types 1 and 2, and show positive uterine ultrasound and uterine artery blood flow dynamics over follow-up. A limitation explicitly acknowledged in the design is that the paper does not provide detailed randomization/blinding information in the provided text and focuses on post-COVID management features rather than isolating specific causal mechanisms for each biomarker change. Relevance to endometriosis: adenomyosis is the main subject, and the study frames post-COVID adenomyosis management; it does not center endometriosis as a comparator condition, but it remains directly relevant to endometriosis-spectrum gynecologic disease through shared pelvic pathology themes, making it centrally about adenomyosis after COVID-19 and management algorithms.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Objectives: development of an algorithm for managing women of reproductive age with adenomyosis of I–IV degrees of severity after COVID-19 by studying anamnestic, clinical, laboratory indicators, results of instrumental and hardware research and determining personalized therapy and prevention.Materials and methods. We monitored 120 reproductive aged women with adenomyosis after COVID-19, who were divided into group B (60 women with adenomyosis of the I–II degree of severity) and group C (60 women with adenomyosis of the III–IV degree of severity). Groups B and C were divided into 2 subgroups: subgroups B1 and C1 received the proposed therapy; subgroups B2 and C2 received standard therapy.All women underwent a clinical and laboratory examination, which included the study of the general condition, clinical and biochemical parameters, examination of biological fluids (blood, urine, vaginal contents), histomorphological study of the tissues of uterus, ovaries, hardware and instrumental methods of examination. The results were evaluated before treatment, after 3, 6 and 12 months of therapy, comparing between groups B and C.Results. The effectiveness of the proposed algorithm is confirmed by a significant difference (p < 0.05) in the reduction of the frequency of complaints, symptoms of exacerbation of extragenital and gynecological pathology, stabilization of indicators of general blood test, functional liver tests, lipid and cholesterol metabolism, reduction of indicators of hypercoagulation, activity of biological markers of inflammatory processes, increase the vitamin D and magnesium values, positive changes in the vaginal biocenosis, a decrease in the frequency of herpes simplex virus types 1 and 2 detection, an increase in the number of Lactobacillus sp., positive dynamics of uterine ultrasound parameters, including the state of blood flow in a. uterus in the observation dynamics after 3, 6 and 12 months.Conclusions. Women of reproductive age with adenomyosis of various degrees of severity after suffering from the COVID-19 disease are subject to personalized dispensary supervision, which includes diagnostic, therapeutic, preventive measures in the dynamics of observation. The definition of the measures of such algorithm should be based on the results of proven pathological changes in the body, namely: exacerbation of extragenital diseases, combined gynecological pathology, blood hypercoagulation and microcirculation disorders, activity of biological markers of inflammation, levels of sex hormones, vitamin D, magnesium, state of vaginal biocenosis.
Full text 9,242 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Objectives

development of an algorithm for managing women of reproductive age with adenomyosis of I–IV degrees of severity after COVID-19 by studying anamnestic, clinical, laboratory indicators, results of instrumental and hardware research and determining personalized therapy and prevention.

Materials

and methods. We monitored 120 reproductive aged women with adenomyosis after COVID-19, who were divided into group B (60 women with adenomyosis of the I–II degree of severity) and group C (60 women with adenomyosis of the III–IV degree of severity). Groups B and C were divided into 2 subgroups: subgroups B1 and C1 received the proposed therapy; subgroups B2 and C2 received standard therapy. All women underwent a clinical and laboratory examination, which included the study of the general condition, clinical and biochemical parameters, examination of biological fluids (blood, urine, vaginal contents), histomorphological study of the tissues of uterus, ovaries, hardware and instrumental methods of examination. The results were evaluated before treatment, after 3, 6 and 12 months of therapy, comparing between groups B and C. Results. The effectiveness of the proposed algorithm is confirmed by a significant difference (p < 0.05) in the reduction of the frequency of complaints, symptoms of exacerbation of extragenital and gynecological pathology, stabilization of indicators of general blood test, functional liver tests, lipid and cholesterol metabolism, reduction of indicators of hypercoagulation, activity of biological markers of inflammatory processes, increase the vitamin D and magnesium values, positive changes in the vaginal biocenosis, a decrease in the frequency of herpes simplex virus types 1 and 2 detection, an increase in the number of Lactobacillus sp., positive dynamics of uterine ultrasound parameters, including the state of blood flow in a. uterus in the observation dynamics after 3, 6 and 12 months. Conclusions. Women of reproductive age with adenomyosis of various degrees of severity after suffering from the COVID-19 disease are subject to personalized dispensary supervision, which includes diagnostic, therapeutic, preventive measures in the dynamics of observation. The definition of the measures of such algorithm should be based on the results of proven pathological changes in the body, namely: exacerbation of extragenital diseases, combined gynecological pathology, blood hypercoagulation and microcirculation disorders, activity of biological markers of inflammation, levels of sex hormones, vitamin D, magnesium, state of vaginal biocenosis.

References

- Bakun, O.V., Tkachuk, A.I. “Influence of genital endometriosis and concomitant diseases on infertility under the data of the retrospective analysis of case histories.” Bukovinian Medical Herald 4.92 (2019): 9–15. - Bulavenko, O.V., Bodnarchuk, O.V., Honcharenko, O.M., et al. “Dynamics of markers of lipid metabolism during combined preventive therapy of pregnant women with obesity and reduced vitamin D status.” Reproductive Endocrinology 4.66 (2022): 54–60. DOI: 10.18370/2309-4117.2022.66.54-60 - Goncharenko, G.Y. “The role of estrogen and progesterone receptors in postmenopausal women with adenomyosis.” Bulletin of the Vinnytsia National Medical University 1.23 (2019): 148–52. DOI: 10.31393/reports-vnmedical-2019-23(1)-26 - Medvedіev, M.V., Pokrovenko, D.A. “A modern view of the etiology, pathogenesis and diagnostic possibilities of external genital endometriosis (literature review).” Medical perspectives 24.1 (2019): 21–30. DOI: 10.26641/2307-0404.2019.1.162173 - Potapov, V.O. “Adenomyosis: problematic issues of treatment.” Obstetrics Gynecology Reproduction 2.43 (2021): Available from: [health-ua.com/article/65800-adenomioz-problemn-pitanny-likuvannya]. - Pryputnevich, T.V., Gordeev, A.B., Lyubasovskaya, L.A., et al. “The new coronavirus SARS-COV-2 and pregnancy: a literature review.” Obstetrics and gynecology 5 (2020): 6–12. DOI: 10.18565/aig.2020.5.6-12 - Senchuk, A.Y., Ventskivskyi, B.M., Tytov, A.V., et al. “Hereditary and acquired thrombophilias in obstetrics and gynecology practice.” Kyiv (2003): 84 p. - Tatarchuk, T.F., Zakharenko, N.F., Reheda, S.I., et al. “Algorithms for prescribing menopausal hormone therapy in different periods of menopause.” Reproductive Endocrinology 4.66 (2022): 68–70. DOI: 10.18370/2309-4117.2022.66.68-70 - Andreev, T.S., Kleimenova, A.O., Drobintseva, V.O., et al. “Signal molecules in volvedin the fermatio of new nerve endingsin endometriosis (literature review).” Swing scientific results of biomedical research 5 (2019): 94–107. - Chen, G., Wu, D., Guo, W., et al. “Clinical and immunological features of severe and moderate coronavirus disease 2019.” J Clin Inverst 13.5 (2020): 2620–9. DOI: 10.1172/JCI137244 - Ding, T., Zhang, J., Wang, T., et al. “Potential influence of menstrual status and sex hormones on female SARS-CoV-2 infection: a cross-sectional study from multicentre in Wuhan, China.” Clin Infect Dis 72.9 (2021): e240–8. DOI: 10.1093/cid/ciaa1022 - Gebhard, C., Regitz-Zagrosek, V., Neuhauser, H.K., et al. “Impact of sex and gender on COVID-19 outcomes in Europe.” Biology of Sex Differences 11.1 (2020): 29. DOI: 10.1186/s13293-020-00304-9 - Ghandehari, S., Matusov, Y., Pepkowitz, S., et al. “Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized with Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial.” Chest 160.1 (2021): 74–84. DOI: 10.1016/j.chest.2021.02.024 - Guerriero, S., Condous, G., van den Bosch, T., et al. “Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group.” Ultrasound Obstet Gynecol 48.3 (2016): 318–32. - Harada, T., Kline, Y.M., Kaponis, A., et al. “The Impact of Adenjmyosis on Women’s Fertility.” Obstet Gynecol Surv 71.9 (2016): 557–68. DOI: 10.1097/OGX.0000000000000346 - Johnson, N.P., Hummelshoj, L., Adamson, G.D., et al. “World Endometriosis Society consensus on the classification of endometriosis.” Hum Reprod 32.2 (2017): 315–24. - Lippi, G., Plebani, M., Henry, B.M. “Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.” Clin Chim Acta 506 (2020): 145–8. DOI: 10.1016/j.cca.2020.03.022 - Martire, F.G., Lazzeri, L., Conway, F., et al. “Adolescence and endometriosis: symptoms, ultrasound signs and early diagnosis.” Fertil Steril 114.5 (2020): 1049–57. - Richardson, S., Hirsch, J.S., Narasimhan, M., et al. “Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area.” JAMA 323.20 (2020): 2052–9. - Rolla, E. “Endometriosis: advances and controversies in classification, pathogenesis, diagnosis, and treatment.” F1000Research 8 (2019): F1000 Faculty Rev-529. DOI: 10.12688/f1000research.14817.1 - Rozhkovskaya, N.M., Sitnikova, V.O., Sivyi, S.M., Lomakina, I.S. “Clinical and morphological features of combined hyperplastic diseases of the uterus against the background of adenomyosis.” Journal of education health and sport 10.4 (2020): 226–33. DOI: 10.12775/JEHS.2020.10.04.025 - Singh, S.S., Suen, M.W. “Surgery for endometriosis: beyond medical therapies.” Fertil Steril 107.3 (2017): 549–54. DOI: 10.1016/j.fertnstert.2017.01.001 - Tang, N., Bai, H., Chen, X., et al. “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy” J Thromb Haemost 18.5 (2020): 1094–9. DOI: 10.1111/jth.14817 - Tang, N., Li, D., Wang, X., Sun, Z. “Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.” J Thromb Haemost 18.4 (2020): 844–7. DOI: 10.1111/jth.14768 - Varga, Z., Flammer, A.J., Steiger, P., et al. “Endothelial cell infection and endotheliitis in COVID-19.” The Lancet 395.10234 (2020): 1417–8. DOI: 10.1016/S0140-6736(20)30937-5 - World Health Organization. WHO Coronavirus (COVID-19) Dashboard (2020). Available from: [https://covid19.who.int/]. Downloads Published How to Cite Issue Section License Copyright (c) 2023 А.В. Булгар, М.Б. Запорожченко This work is licensed under a Creative Commons Attribution 4.0 International License. Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (23)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK